Johnson & Johnson's Vaccine Is Less Effective Than Rivals. Here's Why It Could Still Win Big

Johnson & Johnson (NYSE:JNJ) is about to cross the coronavirus vaccine race finish line. But cheers may not be as loud as they were for rivals Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA). That's because the big pharmaceutical company reported efficacy that lagged that of those earlier-to-market rivals.